Novo brings real-world Wegovy vs resmetirom MASH data to The Liver Meeting
Twelve Novo abstracts head to Denver, including a 5,000-patient records study comparing semaglutide and resmetirom, plus four on efruxifermin.
Recap by typeshit. Full story at Longevity.Technology.